Current Trials

Name No. For Patients with Purpose
AbbVie M14-239 18-49

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).


Name No. For Patients with Purpose
AcceleRET-Lung 20-21

This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.

AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).


Name No. For Patients with Purpose
Add-Asprin 16-19

Non-metastatic breast, colorectal, gastro-oesophagal or prostate cancer which can be treated and potentially cured.

The purpose of this study is to evaluate the the effects of aspirin on disease recurrence and survival in patients who have had primary curative therapy for common non-metastatic solid tumours.


Name No. For Patients with Purpose
ALEXANDRA/IMpassion030 17-15 (WO39391 / BIG 16-05)

Early stage breast cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab.


Name No. For Patients with Purpose
Astellas 8951-CL-5201 CTRIAL-IE 18-44

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

This study will asses the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM)


Name No. For Patients with Purpose
BCNI GMI-1271-301 21-08

Relapsed/Refractory Acute Myeloid Leukemia (AML)

This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia


Name No. For Patients with Purpose
BI Afatinib Trial CTRIAL-IE 18-23

To determine the maximum tolerated dose (MTD), safety, and efficacy of afatinib monotherapy


Name No. For Patients with Purpose
BMS CA045-001 CTRIAL-IE 18-51

Melanoma.

This study will evaluate the efficacy of NKTR-214 Combined with Nivolumab Versus Nivolumab


Name No. For Patients with Purpose
BMS CA209-8FC CTRIAL-IE 19-13

Melanoma.

The study will compare the pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C


Name No. For Patients with Purpose
BMS CA209-8HW 18-08

Metastatic colorectal cancer (mCRC)

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).


Name No. For Patients with Purpose
CA045-001 18-51

Previously untreated or unresectable or Metastatic Melanoma

The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread.


Name No. For Patients with Purpose
CA209-73L / CheckMate 73L 19-25

Participants with previously untreated Locally Advanced Non-Small Cell Lung Cancer.

This study is looking at adding nivolumab to chemoradiotherapy and comparing it to chemoradiotherapy alone. It is also comparing 3 different immunotherapy treatments to have after these first treatments.


Name No. For Patients with Purpose
CA209-77T 19-26

Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

The purpose of this study is to see if treatment with nivolumab in combination with chemotherapy before the surgery followed by treatment with nivolumab after the surgery is better at preventing the return of the cancer and better at improving survival when compared to treatment with chemotherapy alone.


Name No. For Patients with Purpose
CA209-7FL 19-35

high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer

The purpose of this trial is to evaluate the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy


Name No. For Patients with Purpose
CA224-104 21-12

Participants with previously untreated Stage IV Non-Small Cell Lung Cancer.

The objective of the trial is to confirm the dose safety of combination relatlimab and nivolumab plus chemo and to compare the progression free survival for patients with untreated stage IV Non-Small Cell Lung Cancer or Recurrent Non-small Cell Lung Cancer.